Our strategy is to develop our portfolio of innovative products for two large market categories, sexual health and pain to late stage, and then partner with major pharmaceutical partners at the optimum time to generate most value.
We are investing in our lead product MED3000 to generate most value for shareholders.
Increasing Futura and MED3000’s profile in the medical and investment community.
We are focused on innovative products that are highly differentiated in their markets.
Phase 3 FM57 study demonstrates that MED3000 was shown to be a highly effective and a safe treatment for ED across all ED severities.
We aim to improve treatments to give more choice to patients and doctors and improve the quality of life of those suffering from ED and local pain.
MED3000 presents an opportunity for use as a combination treatment with existing treatments (such as PDE5 inhibitors) where patients require greater efficacy offering the potential for a large new patient segment.
We are focused on increasing value for shareholders and the quality of life for patients.
Increase the profile of MED3000 and value of its unique commercial proposition to potential commercial partners on the back of the anticipated data readout trial data to out–license MED3000.